Company Asarina Pharma AB (publ) Nasdaq Stockholm

Asarina Pharma AB (publ), formerly Umecrine Mood, is a Sweden-based biotech company within area of women’s health. The Company’s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The Company conducts trials in Europe. The Company’s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.